{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-038917","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.656444+00:00","generated_at":"2026-06-11T16:50:43.397403+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Femasys Q2 net loss $2.9M; starts FemBloc pivotal trial; appoints COO","bullets":["Q2 net loss $2.9M ($0.22 EPS), revenue $320K (+$17K YoY) from first international sales of $58K.","Cash $10.7M at June 30; expected to fund operations into Q2 2024.","Patient enrollment commenced in FINALE pivotal trial for FemBloc permanent birth control after FDA IDE approval.","Daniel Currie appointed COO with base salary $389K and 40% bonus target.","Received three Health Canada approvals for FemaSeed, FemCerv, FemCath in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-038917","json":"https://secwatch.observer/filing/0001140361-23-038917.json","markdown":"https://secwatch.observer/filing/0001140361-23-038917.md","text":"https://secwatch.observer/filing/0001140361-23-038917.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123038917/0001140361-23-038917-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123038917/brhc20057313_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T16:50:43.397403+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9aa4f25f67ce9723e0534716b53e245a6efacf08","claim":"FEMASYS INC reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"announced its financial results for the second quarter ended June 30, 2023 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123038917/0001140361-23-038917-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9147fdd8c7","claim":"Daniel Currie was appointed as Chief Operating Officer at FEMASYS INC.","evidence_excerpt":"On August 10, 2023, the Company announced that it has designated Daniel Currie, the Company’s Senior Vice President, as its Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123038917/0001140361-23-038917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}